Improving efficacy and reducing toxicity of anti-PD-L1 treatment: T-cells as delivery vehicles for anti-PD-L1 blocking nanobodies

被引：0
|
作者：
Petit, P-F. [1 ]
Zhu, J. [1 ]
van den Eynde, B. J. [1 ]
机构：
[1] Ludwig Inst Canc Res, De Duve Inst, Brussels, Belgium
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.10.511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
25P
引用
收藏
页码：S1425 / S1425
页数：1
相关论文
共 50 条
  • [1] Benefit with anti-PD-L1
    Diana Romero
    Nature Reviews Clinical Oncology, 2017, 14 : 71 - 71
  • [2] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
    Simeone, Ester
    Grimaldi, Antonio M.
    Ascierto, Paolo A.
    MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50
  • [3] Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
    Jiming Chen
    Jie Yang
    Wenhui Wang
    Danfeng Guo
    Chengyan Zhang
    Shibo Wang
    Xinliang Lu
    Xiaofang Huang
    Pingli Wang
    Gensheng Zhang
    Jing Zhang
    Jianli Wang
    Zhijian Cai
    Cellular & Molecular Immunology, 2022, 19 : 1290 - 1301
  • [4] Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
    Chen, Jiming
    Yang, Jie
    Wang, Wenhui
    Guo, Danfeng
    Zhang, Chengyan
    Wang, Shibo
    Lu, Xinliang
    Huang, Xiaofang
    Wang, Pingli
    Zhang, Gensheng
    Zhang, Jing
    Wang, Jianli
    Cai, Zhijian
    CELLULAR & MOLECULAR IMMUNOLOGY, 2022, 19 (11) : 1290 - 1301
  • [5] Hyperprogressive disease with anti-PD-1 and anti-PD-L1
    Brower, Vicki
    LANCET ONCOLOGY, 2016, 17 (12): : E527 - E527
  • [6] IMMUNOTHERAPY Benefit with anti-PD-L1
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (02) : 70 - 70
  • [7] The augment of regulatory T cells undermines the efficacy of anti-PD-L1 treatment in cervical cancer
    Xu, Fengying
    Zhang, Fengying
    Wang, Qian
    Xu, Ying
    Xu, Shuifang
    Zhang, Caihong
    Wang, Lihua
    BMC IMMUNOLOGY, 2021, 22 (01)
  • [8] The augment of regulatory T cells undermines the efficacy of anti-PD-L1 treatment in cervical cancer
    Fengying Xu
    Fengying Zhang
    Qian Wang
    Ying Xu
    Shuifang Xu
    Caihong Zhang
    Lihua Wang
    BMC Immunology, 22
  • [9] Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
    Philips, George K.
    Atkins, Michael
    INTERNATIONAL IMMUNOLOGY, 2015, 27 (01) : 39 - 46
  • [10] Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
    Puccini, Alberto
    Battaglin, Francesca
    Iaia, Maria Laura
    Lenz, Heinz-Josef
    Salem, Mohamed E.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
12345